Clinical Trial Update: An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy [Phase 2]

View source ↗

Summary

Open-label Phase 2 extension study evaluating higher-dose sialic acid formulations (SA-ER and SA-IR) in GNE myopathy; study completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gne Myopathy
• Hereditary Inclusion Body Myopathy

Drugs mentioned

• Sialic Acid Extended Release (SA-ER) tablets (N-acetylneuraminic acid)
• Sialic Acid Immediate Release (SA-IR) capsules (N-acetylneuraminic acid)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: GNE Myopathy, Hereditary Inclusion Body Myopathy (HIBM) | Phase 2 | Status: COMPLETED | Results posted: 2018-03-13